Australia markets closed

Rhythm Pharmaceuticals, Inc. (RYTM)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
37.43-1.74 (-4.44%)
As of 03:32PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 2.39B
Enterprise value 2.19B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)24.94
Price/book (mrq)38.78
Enterprise value/revenue 23.80
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.93
52-week change 3133.57%
S&P500 52-week change 326.36%
52-week high 352.57
52-week low 315.50
50-day moving average 340.32
200-day moving average 335.37

Share statistics

Avg vol (3-month) 3566.66k
Avg vol (10-day) 3643.14k
Shares outstanding 560.97M
Implied shares outstanding 660.97M
Float 845.62M
% held by insiders 10.54%
% held by institutions 1116.11%
Shares short (30 Apr 2024) 410.59M
Short ratio (30 Apr 2024) 421.8
Short % of float (30 Apr 2024) 426.60%
Short % of shares outstanding (30 Apr 2024) 417.37%
Shares short (prior month 28 Mar 2024) 49.74M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -297.93%
Operating margin (ttm)-538.71%

Management effectiveness

Return on assets (ttm)-56.20%
Return on equity (ttm)-194.69%

Income statement

Revenue (ttm)91.93M
Revenue per share (ttm)1.57
Quarterly revenue growth (yoy)126.40%
Gross profit (ttm)N/A
EBITDA -270.01M
Net income avi to common (ttm)-273.87M
Diluted EPS (ttm)-4.63
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)201.2M
Total cash per share (mrq)3.3
Total debt (mrq)108.44M
Total debt/equity (mrq)176.10%
Current ratio (mrq)4.35
Book value per share (mrq)1.01

Cash flow statement

Operating cash flow (ttm)-140.47M
Levered free cash flow (ttm)-188.31M